Cyclooxygenase-2 expression correlates with phaeochromocytoma malignancy: Evidence for a Bcl-2-dependent mechanism

Histopathology

Volumn 51, Issue 6, 2007, Pages 743-751

  Cadden, I S ^b   Atkinson, A B ^c   Johnston, B T ^b   Pogue, K ^b   Connolly, R ^b   McCance, D ^c   Ardill, J E S ^b   Russell, C F ^c   McGinty, A ^a,b  

^a RGH ^*  (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Cancer; Cyclooxygenase; Immunohistochemistry; Neuroendocrine; Phaeochromocytoma

Indexed keywords

CYCLOOXYGENASE 2; ONCOPROTEIN; PROTEIN BCL 2;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR RECURRENCE;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHEOCHROMOCYTOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL;

EID: 36549076442     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02846.x     Document Type: Article

References (25)

1. Ellison DA, Parham DM. Tumours of the autonomic nervous system. Am. J. Clin. Pathol. 2001 115 (suppl. S46 S55.
2. Goldstein RE, O'Neill JA Jr., Holcomb GW 3rd. et al. Clinical experience over 48 years with phaeochromocytoma. Ann. Surg. 1999 229 755 764 discussion 764 766.
3. Beatty OL, Russell CF, Kennedy L, Hadden DR, Kennedy TL, Atkinson AB. Phaeochromocytoma in Northern Ireland: a 21 year review. Eur. J. Surg. 1996 162 695 702.
4. Proye C, Vix M, Goropoulos A, Kerlo P, Lecomte-Houcke M. High incidence of malignant phaeochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991. J. Endocrinol. Invest. 1992 15 651 663.
5. Linnoila RI, Keiser HR, Steinberg SM, Lack EE. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum. Pathol. 1990 21 1168 1180.
6. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat. 2002 69 95 114.
7. Sano H, Kawahito Y, Wilder RL et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995 55 3785 3789.
8. Klimp AH, Hollema H, Kempinga C, van der Zee AG, de Vries EG, Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumours and tumour-associated macrophages. Cancer Res. 2001 61 7305 7309.
9. Sheehan KM, Sheahan K, O'Donoghue DP et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999 282 1254 1257.
10. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995 83 493 501.
11. Liu CH, Chang SH, Narko K et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumourigenesis in transgenic mice. J. Biol. Chem. 2001 276 18563 18569.
12. 2 in human colon cancer cells. Cancer Res. 1998 58 362 366.
13. 1 protects cultured spinal neurons against the effects of nitric oxide toxicity. Neuropharmacology 2002 42 714 723.
14. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994 107 1183 1188.
15. Heaney AP, O'Rourke D, Arthur K, Beatty OL, Russell CF, Sloan JM. Flow cytometric analysis does not reliably differentiate benign from malignant phaeochromocytoma. Clin. Endocrinol. 1996 44 233 238.
16. Salmenkivi K, Haglund C, Ristimaki A, Arola J, Heikkila P. Increased expression of cyclooxygenase-2 in malignant phaeochromocytomas. J. Clin. Endocrinol. Metab. 2001 86 5615 5619.
17. Sonoshita M, Takaku K, Oshima M, Sugihara K, Taketo MM. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res. 2002 62 6846 6849.
18. Ohta K, Iwai K, Kasahara Y et al. Immunoblot analysis of cellular expression of Bcl-2 family proteins, Bcl-2, Bax, Bcl-X and Mcl-1, in human peripheral blood and lymphoid tissues. Int. Immunol. 1995 7 1817 1825.
19. Helin HT, Isola JJ, Helin MJ, Helle MJ, Krohn KJE. Imprint cytology in immunocytochemical analysis of oestrogen and progesterone receptors of breast carcinoma. J. Clin. Pathol. 1989 42 1043 1045.
20. Moyana TN, Xiang J, Senthilselvan A, Kulaga A. The spectrum of neuroendocrine differentiation among gastrointestinal carcinoids: Importance of histologic grading, MIB-1, p53, and bcl-2 immunoreactivity. Arch. Pathol. Lab. Med. 2000 124 570 576.
21. Wang DG, Johnston CF, Marley JJ et al. Expression of the apoptosis-suppressing gene BCL-2 in phaeochromocytoma is associated with the expression of C-MYC. J. Clin. Endocrinol. Metab. 1997 82 1949 1952.
22. de Krijger RR, van der Harst E, van der Ham F et al. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J. Pathol. 1999 188 51 55.
23. Tanji N, Kikugawa T, Yokoyama M. Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and bcl-2 protein expression. Anticancer Res. 2000 20 2313 2319.
24. Aoki T, Tsukinoki K, Karakida K, Ota Y, Otsuru M, Kaneko A. Expression of cyclooxygenase-2, Bcl-2 and Ki-67 in pleomorphic adenoma with special reference to tumour proliferation and apoptosis. Oral Oncol. 2004 40 954 959.
25. Loogna P, Franzen L, Sipponen P, Domellof L. Cyclooxygenase-2 and Bcl-2 expression in the stomach mucosa of Wistar rats exposed to Heliobacter pylori, N-methyl-N-nitrosoguanidine and bile. Virchows Arch. 2002 441 77 84.